Molecular Characterization for Understanding Biliary Atresia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorInstitut National de la Santé Et de la Recherche Médicale, France

About this trial

Although considered a rare disease, Biliary Atresia (BA) is the leading cause of neonatal cholestasis and liver transplantation in children. Little is known about the molecular mechanisms that drive BA. The purpose of this study is to collect the fluid samples, explanted liver tissue samples and dermal biopsy samples to enable investigators to perform the genetic and molecular analyses that might point to the gene(s) and cellular pathway involved in etiology of BA disease.

Eligibility criteria

Qualifiers

confirmed diagnosis of biliary atresia in patients

parents of BA patients

Disqualifiers

no

Trial design

Treatments tested in this trial

  • blood sampling
  • skin biopsy sampling
  • explanted liver of BA patients sampling

Treatment groups

100 Participants
are divided into 1 treatment group